TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10574604

Group type: EXPERIMENTAL
Intervention: p16INK4A protein immunoreactivity
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: pRb detection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: p53 overexpression
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MDM2 positivity
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: EBER 1/2-transcripts detection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Correlation of p16INK4A and MDM2 immunoreactivity with HRS cells
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: pRb-positive neoplastic cells in relation to p16-positive cells
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clinicopathological parameters and clinical prognostic indicators
Number of subjects: 44
Study: 8917172

Group type: EXPERIMENTAL
Intervention: Talking during FDG uptake period
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Talking intermittently during FDG uptake period
Number of subjects: 24

Group type: COMPARATOR
Intervention: Remaining silent during FDG uptake period
Number of subjects: 24
Study: 1801564

Group type: EXPERIMENTAL
Intervention: Men who quit smoking
Number of subjects: 6569

Group type: COMPARATOR
Intervention: Men who continued smoking
Number of subjects: 6569
Study: 2938688

Group type: EXPERIMENTAL
Intervention: Arginine aspartate 37.5 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amino acids without arginine or aspartate (placebo)
Number of subjects: 0
Study: 29530622

Group type: EXPERIMENTAL
Intervention: Capsaicin (2 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 40
Study: 27495917

Group type: EXPERIMENTAL
Intervention: Suggested Alternatives
Number of subjects: 6375

Group type: EXPERIMENTAL
Intervention: Peer Comparison
Number of subjects: 6375

Group type: EXPERIMENTAL
Intervention: Accountable Justifications
Number of subjects: 6375

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6375
Study: 24508364

Group type: COMPARATOR
Intervention: Echocardiography optimized for strain analysis including three RV apical views
Number of subjects: 40
Study: 23054576

Group type: EXPERIMENTAL
Intervention: Bioenterics Intragastric Balloon (BIB) - saline-filled (500 ml saline + 10 ml methylene blue)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endobag-Heliosphere - air-filled (950 ml air)
Number of subjects: 60
Study: 19855926

Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate given intravenously once every 3 months
Number of subjects: 158

Group type: COMPARATOR
Intervention: 70 mg alendronate given orally once per week
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 158

Group type: COMPARATOR
Intervention: 70 mg alendronate
Number of subjects: 158
Study: 17984108

Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) increase of 10 mmHg
Number of subjects: 8093

Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP) increase of 10 mmHg
Number of subjects: 8093

Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) increase of 10 mmHg
Number of subjects: 8093

Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) increase of 10 mmHg
Number of subjects: 8093
Study: 17449933

Group type: EXPERIMENTAL
Intervention: Bilateral pericostal bar fixation (Group 1)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Unilateral pericostal bar fixation (Group 2)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Bilateral submuscular bar fixation (Group 3)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Comparison of Group 1 and Group 3
Number of subjects: 113
Study: 15339678

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 9 mg/m2 infused intravenously on days 1 and 15 followed by conventional chemotherapy (MICE regimen: mitoxantrone, cytarabine, etoposide)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) and MICE regimen
Number of subjects: 57
Study: 10791297

Group type: COMPARATOR
Intervention: Metrifonate (MTF) 2.9 mg/kg weekly for 6 months
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metrifonate (MTF) daily to achieve RBC AChE inhibition levels of 85.90%
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metrifonate (MTF)
Number of subjects: 6
Study: 9577683

Group type: EXPERIMENTAL
Intervention: Identification of ito cells with smooth muscle cell anti-actin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Correlation between the number of ito cells and the stage of chronic hepatitis
Number of subjects: 18
Study: 8449581

Group type: EXPERIMENTAL
Intervention: Recombinant HB vaccine (Engerix‐B, 20 micrograms) given to 40 susceptible health-care workers within three days of exposure (Group B)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: A single dose of HBIg (0.06 mg/kg) administered intramuscularly within three days of exposure followed by the first dose of vaccine (20 micrograms) (Group A)
Number of subjects: 107

Group type: COMPARATOR
Intervention: No specific immunoprophylaxis (Group C)
Number of subjects: 107
Study: 3092933

Group type: EXPERIMENTAL
Intervention: Acupuncture after premedication with 100 mg meptazinol (first study)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Acupuncture with 10 mg nalbuphine (second study)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Dummy acupuncture (second study)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Premedication alone (second study)
Number of subjects: 125
Study: 31003138

Group type: EXPERIMENTAL
Intervention: Acute exercise intervention (30 min of moderate-to-high intensity ergometer bicycling)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Habitual exercise
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (placebo exercise, 30 min of light stretching)
Number of subjects: 84
Study: 28448667

Group type: EXPERIMENTAL
Intervention: Facial rejuvenation surgery (face-lift and upper facial rejuvenation)
Number of subjects: 504
Study: 25866234

Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 100 ng/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 200 ng/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 300 ng/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 400 ng/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 500 ng/ml
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels recommended for detecting alcohol use
Number of subjects: 80
Study: 22936539

Group type: EXPERIMENTAL
Intervention: Four weekly multiprofessional senior group meetings including a follow-up home visit
Number of subjects: 459

Group type: COMPARATOR
Intervention: Preventive home visit
Number of subjects: 459
Study: 21705273

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (titrated from 0.5 mg/24 h to a maximum of 4 mg/24 h)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (4 mg/24 h)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (1-3 mg/24 h)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 295
Study: 19508310

Group type: EXPERIMENTAL
Intervention: Moisturizer (urea containing), applied twice daily during a 26-week maintenance phase
Number of subjects: 44

Group type: COMPARATOR
Intervention: No treatment (untreated areas)
Number of subjects: 44
Study: 17067516

Group type: EXPERIMENTAL
Intervention: Specific Program (SP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional Management (CM)
Number of subjects: 26
Study: 12542609

Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine (3 standard injections at 0, 30, and 60 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no medication or vaccination)
Number of subjects: 51
Study: 11460280

Group type: EXPERIMENTAL
Intervention: Nine-row brush head
Number of subjects: 121

Group type: COMPARATOR
Intervention: Eight-row brush head
Number of subjects: 121
Study: 9379571

Group type: EXPERIMENTAL
Intervention: Normal saline solution flush (3 ml)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Heparin solution flush (3 ml of 10 units heparin/ml normal saline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cost-saving implications of normal saline solution
Number of subjects: 150
Study: 8405007

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 150 mg b.i.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 300 mg b.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3485119

Group type: EXPERIMENTAL
Intervention: Chewable aspirin (10-15 mg/kg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Acetaminophen (10-15 mg/kg)
Number of subjects: 59
Study: 31380003

Group type: EXPERIMENTAL
Intervention: Aggressive fluid therapy with 20 mL/kg of ringer lactate infusion within 90 minutes before ERCP and 3 mL/kg/h during ERCP followed by 3 mL/kg/h up to 8 hours
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group received 1.5 mL/kg of ringer lactate infusion during ERCP up to 8 hours later
Number of subjects: 240
Study: 30424738

Group type: EXPERIMENTAL
Intervention: Stay Active at Home programme
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 10
Study: 27430401

Group type: EXPERIMENTAL
Intervention: Cocaine-dependent, methadone-maintained (CD-MM) patients
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cocaine-dependent patients (CD)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy comparison (HC) participants
Number of subjects: 64
Study: 25038314

Group type: EXPERIMENTAL
Intervention: Beta-carotene 10mg orally once a day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference group (no antioxidants)
Number of subjects: 0
Study: 22422386

Group type: EXPERIMENTAL
Intervention: Music group (patient-selected music played via headphones)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Music group and Control group
Number of subjects: 100
Study: 21146749

Group type: EXPERIMENTAL
Intervention: HGF gene therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17605023

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg/day
Number of subjects: 420

Group type: COMPARATOR
Intervention: Calcium/vitamin D supplements
Number of subjects: 420
Study: 16351554

Group type: EXPERIMENTAL
Intervention: Patient satisfaction (measured using a modified version of the CAHPS survey)
Number of subjects: 542
Study: 11522879

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis (BD)
Number of subjects: 10
Study: 9565804

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - 150 mg/kg bolus in 250 ml of 5% dextrose followed by continuous infusion of 12 mg/kg per hour in 500 ml of 5% dextrose over 24 hours for a minimum of 3 days up to a maximum of 5 days.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo - equal volume of placebo administered for the same duration as NAC.
Number of subjects: 50
Study: 21207908

Group type: EXPERIMENTAL
Intervention: Information group (n = 77)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 231
Study: 3357653

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) patch 50 micrograms/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29954359

Group type: EXPERIMENTAL
Intervention: BF Spiromax
Number of subjects: 493

Group type: COMPARATOR
Intervention: BF Turbuhaler
Number of subjects: 493
Study: 26201713

Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg thrice a day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Lactulose (30-120 ml/day)
Number of subjects: 112
Study: 23456311

Group type: EXPERIMENTAL
Intervention: Steps to Respect: A Bullying Prevention Program (STR)
Number of subjects: 1424
Study: 21748313

Group type: COMPARATOR
Intervention: Oral fluids only
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Intravenous Ringer lactate at 125 ml/h
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Intravenous Ringer lactate at 250 ml/h
Number of subjects: 293
Study: 20731977

Group type: EXPERIMENTAL
Intervention: Clinical reminder use among patients with unhealthy drinking (descriptive cohort)
Number of subjects: 22863

Group type: EXPERIMENTAL
Intervention: Documented brief intervention among patients with clinical-reminder use
Number of subjects: 22863

Group type: EXPERIMENTAL
Intervention: Access to clinical reminder and resolution of unhealthy drinking (outcomes cohort)
Number of subjects: 22863
Study: 17634541

Group type: EXPERIMENTAL
Intervention: High levels of IFN gamma receptor
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Complete loss of IFN gamma receptor
Number of subjects: 339
Study: 16129986

Group type: EXPERIMENTAL
Intervention: Paravertebral nerve blockade
Number of subjects: 50

Group type: COMPARATOR
Intervention: Systemic analgesia
Number of subjects: 50
Study: 12325095

Group type: EXPERIMENTAL
Intervention: Large trials
Number of subjects: 0
Study: 10917002

Group type: EXPERIMENTAL
Intervention: 2.5 mEq/l dialysate calcium (DCa)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3 mEq/l dialysate calcium (DCa)
Number of subjects: 20
Study: 9037846

Group type: EXPERIMENTAL
Intervention: Supervised exercise program for 10 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 40
Study: 2056888

Group type: EXPERIMENTAL
Intervention: L-sulpiride (150 mg po/die)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Racemic sulpiride (300 mg po/die)
Number of subjects: 30
Study: 6318655

Group type: EXPERIMENTAL
Intervention: Intranasal human interferon alpha A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30819098

Group type: EXPERIMENTAL
Intervention: Cafeteria intervention for 6 months
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Cafeteria and behavioral intervention for 6 months
Number of subjects: 366

Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 366
Study: 29931092

Group type: EXPERIMENTAL
Intervention: Combo stent
Number of subjects: 572

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 572
Study: 27094556

Group type: EXPERIMENTAL
Intervention: brush‐plus‐rinse treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: brush‐alone treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: dental scaling regimen
Number of subjects: 91
Study: 24138335

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 22555430

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study: 19602539

Group type: EXPERIMENTAL
Intervention: 3‐h group‐based structured education program with personalized steps‐per‐day goals and pedometers
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 3‐h group‐based structured education program with generic time‐based goals
Number of subjects: 87

Group type: COMPARATOR
Intervention: Brief information leaflet (control condition)
Number of subjects: 87
Study: 17848748

Group type: EXPERIMENTAL
Intervention: zoledronic acid (4 mg, iv, every 28 d)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no zoledronic acid)
Number of subjects: 94
Study: 24125844

Group type: EXPERIMENTAL
Intervention: Patients with diffuse fibrosis (T1 < 470 ms)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients without diffuse fibrosis (T1 >= 470 ms)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients with diffuse fibrosis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients without diffuse fibrosis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Correlation with T1 time
Number of subjects: 37
Study: 11194183

Group type: EXPERIMENTAL
Intervention: 1% procyanidin B-2 tonic
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 29
Study: 9061712

Group type: EXPERIMENTAL
Intervention: Behavior modification with a low calorie diet
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Behavior modification with a very low calorie diet
Number of subjects: 158

Group type: COMPARATOR
Intervention: Behavior modification (control group not specified)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity assessment using the Bergman minimal model
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity at 12 months
Number of subjects: 158
Study: 8141692

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg once daily)
Number of subjects: 0
Study: 3533455

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (100 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (0.4 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Proxyphylline and diprophylline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2484920

Group type: EXPERIMENTAL
Intervention: dihydroquinidine (900 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: quinidine (1,650 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: dihydroquinidine
Number of subjects: 14
Study: 31952034

Group type: EXPERIMENTAL
Intervention: Referral for municipal physical rehabilitation (REHAB)
Number of subjects: 146

Group type: COMPARATOR
Intervention: No referral to any postoperative rehabilitation (HOME)
Number of subjects: 146
Study: 31889148

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted hepatitis B vaccine
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent influenza vaccine (ATIV)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-adjuvanted TIV
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Live yellow-fever or varicella-zoster virus (YFV/VZV) vaccines
Number of subjects: 123
Study: 29275580

Group type: EXPERIMENTAL
Intervention: Group C: dose-dense TEC× 4 every 2 weeks with G-CSF
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Group D: sequential EC× 4 (dose-dense)-T × 4 every 2 weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Group A: concurrent TEC× 4 every 3 weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Group B: sequential EC× 4-T × 4 every 3 weeks
Number of subjects: 168
Study: 25185471

Group type: EXPERIMENTAL
Intervention: Charge awareness video (n = 49)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No charge awareness video (n = 51)
Number of subjects: 100
Study: 23274145

Group type: EXPERIMENTAL
Intervention: Atorvastatin test formulation (generic) 20 mg per day for 8 weeks
Number of subjects: 298

Group type: COMPARATOR
Intervention: Atorvastatin reference formulation (original) 20 mg per day for 8 weeks
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Atorvastatin test formulation
Number of subjects: 298

Group type: COMPARATOR
Intervention: Atorvastatin reference formulation
Number of subjects: 298
Study: 20812240

Group type: EXPERIMENTAL
Intervention: Behavior plus nutrition intervention and nutrition education alone (Clinical Trial Group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard of care (Comparison Sample)
Number of subjects: 67
Study: 18471517

Group type: EXPERIMENTAL
Intervention: Pylorus-preserving Whipple procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended drainage procedure (Frey)
Number of subjects: 0
Study: 16504484

Group type: EXPERIMENTAL
Intervention: Group housing (Evolving Consumer Households)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Independent apartments
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both housing conditions
Number of subjects: 112
Study: 15281283

Group type: EXPERIMENTAL
Intervention: Anticancer drugs (33% off label use)
Number of subjects: 396
Study: 10667492

Group type: EXPERIMENTAL
Intervention: IVIG (1 g/kg in four divided doses on days 1, 2, 3, and 6)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (human albumin)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 9059098

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger
Number of subjects: 60

Group type: COMPARATOR
Intervention: No heat and moisture exchanger
Number of subjects: 60
Study: 8364347

Group type: EXPERIMENTAL
Intervention: 150 mg S(+) OXP daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 150 mg R(‐) OXP daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: 75 mg S(+) OXP single dose (normal controls)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 75 mg R(‐) OXP single dose (normal controls)
Number of subjects: 20
Study: 3090864

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (low to moderate doses)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chlordiazepoxide (10 mg tid, active placebo)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-medication group
Number of subjects: 100
Study: 31763959

Group type: EXPERIMENTAL
Intervention: Class III malocclusion group
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 648

Group type: COMPARATOR
Intervention: Different malocclusion groups
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Age values
Number of subjects: 648
Study: 30952575

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300) managed by nurse-assisted patients
Number of subjects: 458

Group type: COMPARATOR
Intervention: Insulin glargine 300 U/mL (Gla-300) managed by physicians
Number of subjects: 458
Study: 28446644

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1969

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1969

Group type: EXPERIMENTAL
Intervention: Total group (CAS and CEA combined)
Number of subjects: 1969

Group type: EXPERIMENTAL
Intervention: Total group (BMI 25-<30)
Number of subjects: 1969
Study: 26300710

Group type: EXPERIMENTAL
Intervention: Ginsenoside Rb1 (1 ng/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12